| Prev Close | 49.15 |
| Day Low/High | 47.50 / 49.80 |
| 52 Wk Low/High | 29.95 / 58.95 |
| Avg Volume | 575.30K |
| Exchange | NASDAQ |
| Shares Outstanding | 40.09M |
| Market Cap | 1.97B |
| EPS | -1.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
New Research Shows Vast Majority Of Oral Surgery Patients Would Choose Non-opioid Medication To Treat Postsurgical Pain If Given The Option
Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction   Â
Short Interest In Pacira Pharmaceuticals Falls 19.5%
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,240,223 share decrease in total short interest for Pacira Pharmaceuticals Inc. , to 5,113,726, a decrease of 19.52% since 02/28/2017.
First Week Of November 17th Options Trading For Pacira Pharmaceuticals (PCRX)
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the November 17th expiration.
Trinity Health And Pacira Pharmaceuticals Announce Collaboration To Decrease Opioid Use Nationwide
Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities
Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira
Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
Pacira Pharmaceuticals Tops 4Q Earnings Expectations
Pacira (PCRX) reported mixed fourth quarter results.
Short Interest Jumps 15.6% For PCRX
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 836,945 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 6,219,273, an increase of 15.55% since 01/13/2017.
Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo
Pacira Pharmaceuticals, Clearside Biomedical and Organovo Holdings are among the premarket biotech movers on Wednesday.
DePuy Synthes Announces Exclusive Co-Promotional Agreement With Pacira Pharmaceuticals, Inc.
EXPAREL® Provides Orthopaedic Patients Long-Lasting, Non-Opioid Postsurgical Pain Control at the Surgical Site
Pacira Pharmaceuticals Reports Preliminary 2016 Revenues Of $276.4 Million
EXPAREL net product sales driven by soft tissue and orthopedic procedures
Choppiness Usually Ends With Some Sort of Decline
Typically, the best way to get sentiment to turn is to take the indexes down.
Interesting PCRX Put And Call Options For August 2017
Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2017 expiration.
